ORFADIN Side Effects

7026704-2 | Diarrhoea, Vomiting
on Sep 15, 2010 Male patient from UNITED KINGDOM , child 5 years of age, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient experienced the following unwanted or unexpected effects: diarrhoea, vomiting. Orfadin dosage: 20 Mg Total Daily Dose (0,95 Mg/kg,1 In 1 D). Patient was hospitalized.

7019533-7 | Abdominal Pain, Faecaloma, Intestinal Obstruction, Nausea, Urine Output Decreased
Patient was taking Orfadin (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), faecaloma, intestinal obstruction, nausea (What is nausea?), urine output decreased on Sep 08, 2010 from UNITED STATES Additional patient health information: Female patient , child 10 years of age, was diagnosed with tyrosinaemia and. Orfadin dosage: 20 Mg, 2 In 1 D. During the same period patient was treated with MIRALAX (View Miralax Review and Miralax Label ). Patient was hospitalized.

7015529-X | Apnoea, Bronchitis, Diarrhoea, Infection, Paresis, Polyneuropathy, Treatment Noncompliance
Adverse event was reported on Sep 08, 2010 by a Male patient taking Orfadin (View Usage) (Dosage: 21 Mg (21 Mg, 1 In 1 D)) was diagnosed with tyrosinaemia and. Location: GERMANY , child 4 years of age, After Orfadin was administered, patient had the following side effects: apnoea, bronchitis (What is bronchitis?), diarrhoea, infection (What is infection?), paresis, polyneuropathy, treatment noncompliance. Patient was hospitalized and became disabled.

7015473-8 | Bronchitis, Diarrhoea, Gait Disturbance, Opisthotonus, Quadriparesis, Treatment Noncompliance
on Sep 08, 2010 Male patient from GERMANY , child 3 years of age, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient experienced the following unwanted or unexpected effects: bronchitis (What is bronchitis?), diarrhoea, gait disturbance, opisthotonus, quadriparesis, treatment noncompliance. Orfadin dosage: 17 Mg (17 Mg, 1 In 1 D) Oral. Patient was hospitalized and became disabled.


7012345-X | Abasia, Bronchitis, Diarrhoea, Opisthotonus, Quadriparesis, Treatment Noncompliance
on Sep 09, 2010 Male patient from DENMARK , child 3 years of age, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient had the following side effects: abasia, bronchitis (What is bronchitis?), diarrhoea, opisthotonus, quadriparesis, treatment noncompliance. Orfadin dosage: 17 Mg (17 Mg, 1 In 1 D) Oral. Patient was hospitalized and became disabled.

7003242-4 | Intestinal Obstruction, Nutritional Condition Abnormal, Urine Output Decreased
Patient was taking Orfadin (View Usage). After Orfadin was administered, patient had the following side effects: intestinal obstruction, nutritional condition abnormal, urine output decreased on Sep 02, 2010 from UNITED STATES Additional patient health information: Female patient , child 10 years of age, was diagnosed with amino acid metabolism disorder and. Orfadin dosage: 20 Mg, 2 In 1 D. Patient was hospitalized.

6747439-7 | Hepatic Fibrosis, Hepatic Neoplasm Malignant, Liver Disorder
Adverse event was reported on May 12, 2010 by a Male patient taking Orfadin (View Usage) (Dosage: 1.07 Mg/kg (30 Mg,1 In 1 D)) was diagnosed with tyrosinaemia and. Location: FRANCE , child 10 years of age, Patient experienced the following unwanted or unexpected effects: hepatic fibrosis, hepatic neoplasm malignant, liver disorder. Patient was hospitalized.

6743558-X | Haemoglobin Decreased, Hepatic Cirrhosis, Hepatic Encephalopathy, Hepatic Enzyme Increased, Hepatic Neoplasm, Hepatosplenomegaly, Jaundice, Liver Transplant, Peritonitis
on May 11, 2010 Male patient from BRAZIL , child 1 years of age, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient had the following side effects: haemoglobin decreased, hepatic cirrhosis, hepatic encephalopathy, hepatic enzyme increased, hepatic neoplasm, hepatosplenomegaly, jaundice (What is jaundice?), liver transplant (What is liver transplant?), peritonitis. Orfadin dosage: 1 Mg/kg. Patient was hospitalized.

6669749-4 | Haemoglobin Decreased, Hepatic Enzyme Increased, Jaundice, Liver Transplant, Platelet Count Decreased, Prothrombin Time Prolonged
on Mar 22, 2010 Male patient from BRAZIL , child 1 years of age, weighting 22.05 lb, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). After Orfadin was administered, patient had the following side effects: haemoglobin decreased, hepatic enzyme increased, jaundice (What is jaundice?), liver transplant (What is liver transplant?), platelet count decreased, prothrombin time prolonged. Orfadin dosage: 1 Mg/ Kg Oral. Patient was hospitalized.

6666182-6 | Bone Marrow Disorder, Disease Progression, Epistaxis, Malignant Neoplasm Progression, Neuroblastoma, Off Label Use, Pancytopenia
Patient was taking Orfadin (View Usage). Patient experienced the following unwanted or unexpected effects: bone marrow disorder, disease progression, epistaxis, malignant neoplasm progression, neuroblastoma (What is neuroblastoma?), off label use, pancytopenia on Mar 15, 2010 from UNITED STATES Additional patient health information: Male patient , child 9 years of age, was diagnosed with off label use and. Orfadin dosage: 10 Mg, 2 In 1 D, Oral. During the same period patient was treated with MEROPENEM (View Meropenem Review and Meropenem Label ), NEXAVAR (View Nexavar Review and Nexavar Label ), DILAUDID (View Dilaudid Review and Dilaudid Label ), OXYCONTIN (View Oxycontin Review and Oxycontin Label ).

6641774-9 | Epistaxis, Off Label Use, Pancytopenia, Platelet Count Decreased
Adverse event was reported on Mar 05, 2010 by a Male patient taking Orfadin (View Usage) (Dosage: 10 Mg, 2 In 1 D, Oral) was diagnosed with neuroblastoma recurrent, off label use and. Location: UNITED STATES , child 9 years of age, Patient had the following side effects: epistaxis, off label use, pancytopenia, platelet count decreased. During the same period patient was treated with MEROPENEM (View Meropenem Review and Meropenem Label ), NEXAVAR (View Nexavar Review and Nexavar Label ), DILAUDID (HYDROMORPHONE) (INJECTION) (View Dilaudid (hydromorphone) (injection) Review and Dilaudid (hydromorphone) (injection) Label ), OXYCONTIN (OXYCODONE) (View Oxycontin (oxycodone) Review and Oxycontin (oxycodone) Label ).

6611028-5 | Alpha 1 Foetoprotein Increased, Hepatic Neoplasm Malignant, Liver Transplant
on Feb 11, 2010 Male patient from BELGIUM , child 6 years of age, weighting 88.18 lb, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). After Orfadin was administered, patient had the following side effects: alpha 1 foetoprotein increased, hepatic neoplasm malignant, liver transplant (What is liver transplant?). Orfadin dosage: 24 Mg (12 Mg, 2 In 1 D) Oral. Patient was hospitalized.

6555208-6 | Alpha 1 Foetoprotein Increased, Hepatic Cirrhosis, Liver Transplant, Transplant Rejection, Viral Infection
on Jan 11, 2010 Female patient from FINLAND , child 1 years of age, weighting 26.46 lb, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient experienced the following unwanted or unexpected effects: alpha 1 foetoprotein increased, hepatic cirrhosis, liver transplant (What is liver transplant?), transplant rejection, viral infection (What is viral infection?). Orfadin dosage: 1.6 Mg/kg(20 Mg, 1 In 1 D), Oral. Patient was hospitalized.

6549767-7 | Alpha 1 Foetoprotein Increased, Hepatic Neoplasm Malignant Resectable
Patient was taking Orfadin (View Usage). Patient had the following side effects: alpha 1 foetoprotein increased, hepatic neoplasm malignant resectable on Jan 05, 2010 from FRANCE Additional patient health information: Male patient , child 8 years of age, was diagnosed with tyrosinaemia and. Orfadin dosage: 0,63 Mg/kg Oral. Patient was hospitalized.

6549189-9 | Alpha 1 Foetoprotein Increased, Cytolytic Hepatitis, Hepatic Adenoma, Hepatic Enzyme Increased, Mental Retardation, Speech Disorder Developmental, Treatment Noncompliance
Adverse event was reported on Jan 05, 2010 by a Female patient taking Orfadin (View Usage) (Dosage: 0.7 Mg/kg (15 Mg, 1 In 1 D), Oral) was diagnosed with tyrosinaemia and. Location: FRANCE , child 6 years of age, After Orfadin was administered, patient had the following side effects: alpha 1 foetoprotein increased, cytolytic hepatitis, hepatic adenoma, hepatic enzyme increased, mental retardation, speech disorder developmental, treatment noncompliance.

6493523-5 | Hepatic Adenoma, Hepatic Neoplasm Malignant, Liver Transplant
on Nov 24, 2009 Male patient from CZECH REPUBLIC , child 2 years of age, weighting 34.83 lb, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient experienced the following unwanted or unexpected effects: hepatic adenoma, hepatic neoplasm malignant, liver transplant (What is liver transplant?). Orfadin dosage: 1 Mg/kg, Oral. Patient was hospitalized.

6491992-8 | Alpha 1 Foetoprotein Increased, Hepatic Adenoma, Hepatic Neoplasm Malignant
on Nov 24, 2009 Male patient from CZECH REPUBLIC , 19 years of age, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient had the following side effects: alpha 1 foetoprotein increased, hepatic adenoma, hepatic neoplasm malignant. Orfadin dosage: 1.07 Mg/kg (60 Mg,1 In 1 D) Oral.

6491337-3 | Amino Acid Level Increased, Cognitive Disorder, Memory Impairment
Patient was taking Orfadin (View Usage). After Orfadin was administered, patient had the following side effects: amino acid level increased, cognitive disorder, memory impairment on Nov 26, 2009 from GERMANY Additional patient health information: Male patient , 13 years of age, was diagnosed with tyrosinaemia and. Orfadin dosage: 0,5 Mg/kg (30 Mg, 1 In 1 D), Oral.

6485130-5 | Alpha 1 Foetoprotein Increased, Hepatic Cirrhosis, Liver Transplant
Adverse event was reported on Nov 19, 2009 by a Female patient taking Orfadin (View Usage) (Dosage: ) was diagnosed with tyrosinaemia and. Location: FINLAND , child 3 years of age, Patient experienced the following unwanted or unexpected effects: alpha 1 foetoprotein increased, hepatic cirrhosis, liver transplant (What is liver transplant?). Patient was hospitalized.

6437877-4 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Duodenal Ulcer, Platelet Count Increased
on Oct 26, 2009 Female patient from FRANCE , child 1 years of age, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, duodenal ulcer, platelet count increased. Orfadin dosage: 10 Mg Oral. During the same period patient was treated with SELENIUM (SELENIUM) (View Selenium (selenium) Review and Selenium (selenium) Label ), OROCAL (CALCIUM CARBONATE) (View Orocal (calcium Carbonate) Review and Orocal (calcium Carbonate) Label ). Patient was hospitalized.

6426624-8 | Alpha 1 Foetoprotein Increased, Hepatic Neoplasm Malignant, Liver Transplant
on Oct 20, 2009 Male patient from CHILE , 16 years of age, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). After Orfadin was administered, patient had the following side effects: alpha 1 foetoprotein increased, hepatic neoplasm malignant, liver transplant (What is liver transplant?). Orfadin dosage: 1 Mg/kg Oral. Patient was hospitalized.

6411195-2 | Activated Partial Thromboplastin Time Prolonged, Condition Aggravated, Gastrointestinal Haemorrhage, Haematocrit Decreased, Haemoglobin Decreased, Hepatosplenomegaly, No Therapeutic Response, Platelet Count Decreased, Prothrombin Time Prolonged
Patient was taking Orfadin (View Usage). Patient experienced the following unwanted or unexpected effects: activated partial thromboplastin time prolonged, condition aggravated, gastrointestinal haemorrhage, haematocrit decreased, haemoglobin decreased, hepatosplenomegaly, no therapeutic response, platelet count decreased, prothrombin time prolonged on Oct 07, 2009 from TURKEY Additional patient health information: Male patient , child 2 years of age, weighting 22.05 lb, was diagnosed with tyrosinaemia and. Orfadin dosage: 2 Mg/kg, 20 Mg Total Daily Dose (20 Mg, 1 In 1 D) Oral.

6407925-6 | Hepatic Neoplasm Malignant, Therapeutic Agent Toxicity
Adverse event was reported on Oct 05, 2009 by a Male patient taking Orfadin (View Usage) (Dosage: 0.63 Mg/kg, Oral) was diagnosed with tyrosinaemia and. Location: FRANCE , child 8 years of age, weighting 59.52 lb, Patient had the following side effects: hepatic neoplasm malignant, therapeutic agent toxicity.

6407759-2 | Amino Acid Level Increased, Cognitive Disorder, Educational Problem, Memory Impairment, Treatment Noncompliance
on Oct 03, 2009 Male patient from GERMANY , 13 years of age, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). After Orfadin was administered, patient had the following side effects: amino acid level increased, cognitive disorder, educational problem, memory impairment, treatment noncompliance. Orfadin dosage: 0.5 Mg/kg (30 Mg,1 In 1 D) Oral.

6342058-9 | Cognitive Disorder, Inadequate Diet
on Aug 24, 2009 Male patient from GERMANY , 13 years of age, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient experienced the following unwanted or unexpected effects: cognitive disorder, inadequate diet. Orfadin dosage: 0,5 Mg/kg (30 Mg, 1 In 1 D).

6270904-6 | Ascites, Condition Aggravated, Liver Transplant, Respiratory Failure
Patient was taking Orfadin (View Usage). Patient had the following side effects: ascites, condition aggravated, liver transplant (What is liver transplant?), respiratory failure on Jul 02, 2009 from UNITED STATES Additional patient health information: Female patient , child 2 years of age, weighting 26.46 lb, was diagnosed with tyrosinaemia and. Orfadin dosage: 1 Mg/kg, 1 In 1 D, Oral. Patient was hospitalized.

6265381-5 | Activated Partial Thromboplastin Time Prolonged, Hepatic Cirrhosis, Hepatic Dysplasia, Hepatic Neoplasm, Liver Transplant, Prothrombin Level Increased, Treatment Noncompliance
Adverse event was reported on Jun 25, 2009 by a Female patient taking Orfadin (View Usage) (Dosage: 1 Mg/kg Oral) was diagnosed with tyrosinaemia and. Location: ARGENTINA , child 6 years of age, After Orfadin was administered, patient had the following side effects: activated partial thromboplastin time prolonged, hepatic cirrhosis, hepatic dysplasia, hepatic neoplasm, liver transplant (What is liver transplant?), prothrombin level increased, treatment noncompliance. Patient was hospitalized.

6238044-X | Brain Oedema
on Jun 05, 2009 Male patient from SWEDEN , child 1 years of age, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient experienced the following unwanted or unexpected effects: brain oedema. Orfadin dosage: 1 Mg/kg (12 Mg,1 In 1 D). During the same period patient was treated with ACETYLSYCTEIN (ACETYLCYSTEIN) (View Acetylsyctein (acetylcystein) Review and Acetylsyctein (acetylcystein) Label ), CEFUROXIM(CEFUROXIM) (View Cefuroxim(cefuroxim) Review and Cefuroxim(cefuroxim) Label ), METRONIDAZOL(METRONIDAZOL) (View Metronidazol(metronidazol) Review and Metronidazol(metronidazol) Label ).

6204541-6 | Liver Transplant
on May 06, 2009 Male patient from UNITED STATES , child 4 years of age, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient had the following side effects: liver transplant (What is liver transplant?). Orfadin dosage: 15 Mg, Oral. Patient was hospitalized.

6188489-1 | Anaemia, Asthenia, Complications Of Transplanted Liver, Failure To Thrive, Fanconi Syndrome, Femur Fracture, Haemorrhage, Hepatomegaly, Hypotonia
Patient was taking Orfadin (View Usage). After Orfadin was administered, patient had the following side effects: anaemia, asthenia, complications of transplanted liver, failure to thrive, fanconi syndrome, femur fracture, haemorrhage, hepatomegaly, hypotonia on Apr 26, 2009 from FRANCE Additional patient health information: Male patient , child 5 years of age, was diagnosed with tyrosinaemia and. Orfadin dosage: 2 Mg/kg, 25 Mg Total Daily Dose, Oral. During the same period patient was treated with PHOSPHORENOUS (PHOSPHORUS) ( DROPS) (View Phosphorenous (phosphorus) ( Drops) Review and Phosphorenous (phosphorus) ( Drops) Label ), CALCIDOSE (CALCIUM) (View Calcidose (calcium) Review and Calcidose (calcium) Label ), BICARBONATE DE SODIUM (SODIUM BICARBONATE) (View Bicarbonate De Sodium (sodium Bicarbonate) Review and Bicarbonate De Sodium (sodium Bicarbonate) Label ), UN ALPHA (VITAMIN D) (DROPS) (View Un-alpha (vitamin D) (drops) Review and Un-alpha (vitamin D) (drops) Label ), LEVOCARNYL (L CARNITINE) (View Levocarnyl (l-carnitine) Review and Levocarnyl (l-carnitine) Label ), FEROSTRANE (IRON) (View Ferostrane (iron) Review and Ferostrane (iron) Label ), SPECIAFOLDINE (FOLATE) (View Speciafoldine (folate) Review and Speciafoldine (folate) Label ). Patient was hospitalized.

6181273-4 | Abdominal Pain, Anorexia, Azotaemia, Dehydration, Economic Problem, Hypertension, Incorrect Dose Administered, Pneumonia, Porphyria Acute
Adverse event was reported on Apr 20, 2009 by a Male patient taking Orfadin (View Usage) (Dosage: 10 Mg (10 Mg, 1 In 1 D), Oral) was diagnosed with tyrosinaemia and. Location: ISRAEL , child 2 years of age, Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), anorexia, azotaemia, dehydration, economic problem, hypertension, incorrect dose administered, pneumonia (What is pneumonia?), porphyria acute. During the same period patient was treated with AUGMENTIN (AMOXICILLIN, CLAVULANATE) (View Augmentin (amoxicillin, Clavulanate) Review and Augmentin (amoxicillin, Clavulanate) Label ). Patient was hospitalized.

6170024-5 | Acute Hepatic Failure, Complications Of Transplanted Liver, Post Procedural Haemorrhage
on Apr 09, 2009 Male patient from FRANCE , child 5 years of age, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient had the following side effects: acute hepatic failure, complications of transplanted liver, post procedural haemorrhage. Orfadin dosage: 2 Mg/kg, 25 Mg Total Daily Dose. During the same period patient was treated with PHOSPHORENOUS (PHOSPHORUS) (DROPS) (View Phosphorenous (phosphorus) (drops) Review and Phosphorenous (phosphorus) (drops) Label ), CALCIDOSE (CALCIUM) (View Calcidose (calcium) Review and Calcidose (calcium) Label ), BICARBONATE DE SODIUM(SODIUM BICARBONATE) (View Bicarbonate De Sodium(sodium Bicarbonate) Review and Bicarbonate De Sodium(sodium Bicarbonate) Label ), UN ALPHA (VITAMIN D) (DROPS) (View Un-alpha (vitamin D) (drops) Review and Un-alpha (vitamin D) (drops) Label ), LEVOCARNYL (L CARNITINE) (View Levocarnyl (l-carnitine) Review and Levocarnyl (l-carnitine) Label ), FEROSTRANE (IRON) (View Ferostrane (iron) Review and Ferostrane (iron) Label ), SPECIAFOLDINE (FOLATE) (View Speciafoldine (folate) Review and Speciafoldine (folate) Label ). Patient was hospitalized.

6163173-9 | Hepatoblastoma, Liver Transplant
on Apr 07, 2009 Male patient from UNITED STATES , child 4 years of age, was diagnosed with amino acid metabolism disorder, tyrosinaemia and was treated with Orfadin (View Usage). After Orfadin was administered, patient had the following side effects: hepatoblastoma, liver transplant (What is liver transplant?). Orfadin dosage: 15 Mg, Oral. Patient was hospitalized.

6127517-6 | Viral Infection, Vomiting
Patient was taking Orfadin (View Usage). Patient experienced the following unwanted or unexpected effects: viral infection (What is viral infection?), vomiting on Mar 04, 2009 from UNITED KINGDOM Additional patient health information: Female patient , 13 years of age, was diagnosed with tyrosinaemia, vomiting and. Orfadin dosage: 30 Mg Oral. Patient was hospitalized.

6119765-6 | Cerebral Haemorrhage
Adverse event was reported on Feb 26, 2009 by a Female patient taking Orfadin (View Usage) (Dosage: 0.96 Mg/kg Oral) was diagnosed with tyrosinaemia and. Location: FRANCE , 16 years of age, Patient had the following side effects: cerebral haemorrhage. Patient was hospitalized.

6073158-9 | Cognitive Disorder, Developmental Delay, Epilepsy
on Jan 26, 2009 Male patient from NETHERLANDS , child 10 years of age, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). After Orfadin was administered, patient had the following side effects: cognitive disorder, developmental delay, epilepsy (What is epilepsy?). Orfadin dosage: 0.89 Mg/kg, Oral.

6039412-1 | Acinetobacter Infection, Acute Respiratory Distress Syndrome, Bacterial Sepsis, Condition Aggravated, Hepatic Failure, Renal Failure Acute
on Dec 29, 2008 Female patient from , weighting 10.36 lb, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient experienced the following unwanted or unexpected effects: acinetobacter infection, acute respiratory distress syndrome, bacterial sepsis, condition aggravated, hepatic failure, renal failure acute. Orfadin dosage: 0,851 Mg/kg, Oral. During the same period patient was treated with FENTANYL (View Fentanyl Review and Fentanyl Label ), DOPAMINE HCL (View Dopamine Hcl Review and Dopamine Hcl Label ), RANITIDINE (View Ranitidine Review and Ranitidine Label ), URSO FALK (View Urso Falk Review and Urso Falk Label ).

5989666-2 | Blood Calcium Decreased, Blood Sodium Decreased, Cardio-respiratory Arrest, Cyanosis, Depressed Level Of Consciousness, Dyspnoea, Hypotonia, Portal Hypertension, Protein Total Decreased
Patient was taking Orfadin (View Usage). Patient had the following side effects: blood calcium decreased, blood sodium decreased, cardio-respiratory arrest, cyanosis, depressed level of consciousness, dyspnoea, hypotonia, portal hypertension, protein total decreased on May 30, 2006 from ISRAEL Additional patient health information: Male patient , child 8 years of age, was diagnosed with tyrosinaemia and. Orfadin dosage: 1 Mg/kg. Patient was hospitalized.

5989265-2 | Abasia, Acute Polyneuropathy, Gastroenteritis, Hyporeflexia, Hypotonia, Myalgia, Paraesthesia
Adverse event was reported on Jul 13, 2006 by a Male patient taking Orfadin (View Usage) (Dosage: 15 Mg (5 Mg,3 In 1 D), Oral) was diagnosed with tyrosinaemia and. Location: CZECH REPUBLIC , child 3 years of age, After Orfadin was administered, patient had the following side effects: abasia, acute polyneuropathy, gastroenteritis (What is gastroenteritis?), hyporeflexia, hypotonia, myalgia, paraesthesia. During the same period patient was treated with L CARNITINE(L CARNITINE) (View L-carnitine(l-carnitine) Review and L-carnitine(l-carnitine) Label ), CALCIUM (CALCIUM) (View Calcium (calcium) Review and Calcium (calcium) Label ), VITAMIN E (View Vitamin E Review and Vitamin E Label ), VITAMIN C (VITAMIN C) (View Vitamin C (vitamin C) Review and Vitamin C (vitamin C) Label ). Patient was hospitalized.

5957339-8 | Hepatic Cirrhosis, Hepatic Failure, Hepatic Neoplasm, Liver Transplant
on Oct 28, 2008 Male patient from UNITED KINGDOM , weighting 14.55 lb, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient experienced the following unwanted or unexpected effects: hepatic cirrhosis, hepatic failure, hepatic neoplasm, liver transplant (What is liver transplant?). Orfadin dosage: 4 Mg, Oral. During the same period patient was treated with CALCIUM SANDOZ (CALCIUM) (View Calcium Sandoz (calcium) Review and Calcium Sandoz (calcium) Label ), VITAMIN A (NATURAL) CAP (View Vitamin A (natural) Cap Review and Vitamin A (natural) Cap Label ), VITAMIN K TAB (View Vitamin K Tab Review and Vitamin K Tab Label ), SPIRONOLACTONE (View Spironolactone Review and Spironolactone Label ).

5955201-8 | Alpha 1 Foetoprotein Increased, Hepatic Cyst
on Oct 28, 2008 Female patient from UNITED KINGDOM , child 1 years of age, weighting 26.57 lb, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient had the following side effects: alpha 1 foetoprotein increased, hepatic cyst. Orfadin dosage: 12 Mg, Oral.

5940669-3 | Condition Aggravated, Hepatic Failure, Leukopenia, Thrombocytopenia
Patient was taking Orfadin (View Usage). After Orfadin was administered, patient had the following side effects: condition aggravated, hepatic failure, leukopenia, thrombocytopenia on Oct 14, 2008 from Additional patient health information: Female patient , weighting 15.43 lb, was diagnosed with tyrosinaemia and. Orfadin dosage: 1,6 Mg/kg, Oral. During the same period patient was treated with GANCICLOVIR (5 Mg/kg) (View Ganciclovir Review and Ganciclovir Label ).

5939466-4 | Alpha 1 Foetoprotein Increased, Hepatic Cirrhosis, Liver Transplant
Adverse event was reported on Jul 08, 2005 by a Female patient taking Orfadin (View Usage) (Dosage: 15 Mg, 1 In 1 D, Oral) was diagnosed with tyrosinaemia and. Location: , child 3 years of age, weighting 31.09 lb, Patient experienced the following unwanted or unexpected effects: alpha 1 foetoprotein increased, hepatic cirrhosis, liver transplant (What is liver transplant?). Patient was hospitalized.

5927712-2 | Abdominal Distension, Ascites, Eyelid Oedema, Peritonitis Bacterial, Pyrexia
on Aug 20, 2003 Female patient from UNITED STATES , child 1 years of age, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient had the following side effects: abdominal distension, ascites, eyelid oedema, peritonitis bacterial, pyrexia. Orfadin dosage: 10 Mg, 2 In 1 D, Oral. During the same period patient was treated with NAHC03 (NAHC03) (View Nahc03 (nahc03) Review and Nahc03 (nahc03) Label ), CIPRO (View Cipro Review and Cipro Label ), ACTIGALL (View Actigall Review and Actigall Label ), LASIX (View Lasix Review and Lasix Label ), ALDACTONE (View Aldactone Review and Aldactone Label ), PREVACID (View Prevacid Review and Prevacid Label ), MAGNESIUM OXIDE (MAGNESIUM OXIDE) (View Magnesium Oxide (magnesium Oxide) Review and Magnesium Oxide (magnesium Oxide) Label ).

5914482-7 | Condition Aggravated, Hepatic Failure, Leukopenia, Thrombocytopenia
on Sep 23, 2008 Female patient from , weighting 15.43 lb, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). After Orfadin was administered, patient had the following side effects: condition aggravated, hepatic failure, leukopenia, thrombocytopenia. Orfadin dosage: 1, 6 Mg/kg, Oral. During the same period patient was treated with GANCICLOVIR (5 Mg/kg) (View Ganciclovir Review and Ganciclovir Label ).

5874629-8 | Haemoglobin Decreased, Hepatic Failure, Liver Transplant, Lymphoma, No Therapeutic Response, Renal Failure
Patient was taking Orfadin (View Usage). Patient experienced the following unwanted or unexpected effects: haemoglobin decreased, hepatic failure, liver transplant (What is liver transplant?), lymphoma (What is lymphoma?), no therapeutic response, renal failure on Aug 15, 2008 from Additional patient health information: Male patient , weighting 24.25 lb, was diagnosed with tyrosinaemia and. Orfadin dosage: Oral. Patient was hospitalized.

5874622-5 | Gastric Varices, Hepatic Cirrhosis, Renal Impairment
Adverse event was reported on Aug 18, 2008 by a Male patient taking Orfadin (View Usage) (Dosage: 21mg Tdd, 1, 35 Mg/kg/day, Oral) was diagnosed with tyrosinaemia and. Location: , weighting 35.27 lb, Patient had the following side effects: gastric varices, hepatic cirrhosis, renal impairment.

5836100-9 | Hepatic Cirrhosis, Renal Impairment
on Jul 22, 2008 Male patient from GERMANY , weighting 35.27 lb, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). After Orfadin was administered, patient had the following side effects: hepatic cirrhosis, renal impairment. Orfadin dosage: 21mg Tdd, 1,35 Mg/kg/day, Oral.

5824586-5 | Grand Mal Convulsion
on Sep 18, 2003 Male patient from SWEDEN , weighting 10.25 lb, was diagnosed with tyrosinaemia and was treated with Orfadin (View Usage). Patient experienced the following unwanted or unexpected effects: grand mal convulsion. Orfadin dosage: 5 Mg, 2 In 1 D, Oral. During the same period patient was treated with ZINIC (ZINC) (View Zinic (zinc) Review and Zinic (zinc) Label ), FUNGIZONE (AMPHOTERICINE B) (View Fungizone (amphotericine B) Review and Fungizone (amphotericine B) Label ), ALDACTONE (View Aldactone Review and Aldactone Label ), MOPRAL (OMEPRAZOLE) (View Mopral (omeprazole) Review and Mopral (omeprazole) Label ), MOTILIUM (View Motilium Review and Motilium Label ), UVESTEROL ADEC (VITAMIN A, VITAMIN D2, VITAMIN C, VITAMINE E) (View Uvesterol Adec (vitamin A, Vitamin D2, Vitamin C, Vitamine E) Review and Uvesterol Adec (vitamin A, Vitamin D2, Vitamin C, Vitamine E) Label ).

5821667-7 | Learning Disorder
Patient was taking Orfadin (View Usage). Patient had the following side effects: learning disorder (What is learning disorder?) on Jul 11, 2008 from SWEDEN Additional patient health information: Male patient , child 4 years of age, weighting 65.70 lb, was diagnosed with tyrosinaemia and. Orfadin dosage: Oral.